Compare Enveric Biosciences Inc (ENVB) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Philip Morris International Inc. — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while Philip Morris International Inc. trades at $186.32 (market cap $281.91B). The key difference: Philip Morris International Inc. is far larger — about 52990.6× Enveric Biosciences Inc's market cap, and Philip Morris International Inc. pays a 3.25% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | PM | |
|---|---|---|
Market Cap | $5.32M | $281.91B |
Sector | Health | Consumer Staples |
52-Week High | $17.40 | $191.86 |
52-Week Low | $1.28 | $144.33 |
Enterprise Value | $408.82K | $328.41B |
Dividend Yield | — | 3.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Philip Morris International (PM) trades at $175.95, down 2.35% amid a bearish technical signal and recent profit forecast revision. The company reported strong Q1 2026 EPS of $1.96, beating estimates, but faces headwinds from a $500 million impairment charge and margin pressures. Revenue growth remains steady, with 2025 revenue at $40.65 billion and net income margin of 26.74%. Analyst consensus is bullish with a $194 price target, though technical indicators show resistance near $179.
The stock presents a mixed outlook: solid fundamentals and high analyst buy ratings support upside potential, but near-term risks include cost pressures, currency volatility, and illicit market growth. Long-term investors may find value in the dividend and brand strength, while caution is warranted due to regulatory and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
